CAM
STOK icon

Cormorant Asset Management’s Stoke Therapeutics STOK Stock Holding History

Cormorant Asset Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-254,161
Closed -$2.88M – 41
2025
Q2 		$2.88M Hold
254,161
– – 0.21% 39
2025
Q1 		$1.69M Hold
254,161
– – 0.13% 43
2024
Q4 		$2.8M Sell
254,161
-173,002
-41% -$2.13M 0.15% 44
2024
Q3 		$5.25M Hold
427,163
– – 0.28% 39
2024
Q2 		$5.77M Hold
427,163
– – 0.33% 42
2024
Q1 		$5.77M Sell
427,163
-660,644
-61% -$4M 0.25% 52
2023
Q4 		$5.72M Hold
1,087,807
– – 0.27% 39
2023
Q3 		$4.29M Hold
1,087,807
– – 0.25% 40
2023
Q2 		$11.6M Hold
1,087,807
– – 0.65% 36
2023
Q1 		$9.06M Hold
1,087,807
– – 0.6% 40
2022
Q4 		$10M Hold
1,087,807
– – 0.67% 39
2022
Q3 		$14M Hold
1,087,807
– – 0.98% 36
2022
Q2 		$14.4M Hold
1,087,807
– – 1.09% 31
2022
Q1 		$22.9M Sell
1,087,807
-94,555
-8% -$1.89M 1.76% 16
2021
Q4 		$28.4M Sell
1,182,362
-95,914
-8% -$2.29M 1.69% 19
2021
Q3 		$32.5M Hold
1,278,276
– – 1.32% 23
2021
Q2 		$43M Sell
1,278,276
-159,531
-11% -$5.64M 1.46% 23
2021
Q1 		$55.8M Hold
1,437,807
– – 1.24% 19
2020
Q4 		$89M Sell
1,437,807
-100,000
-7% -$4.58M 2.12% 12
2020
Q3 		$51.5M Sell
1,537,807
-163,485
-10% -$4.67M 1.98% 17
2020
Q2 		$40.5M Sell
1,701,292
-8,473
-0.5% -$201K 1.55% 25
2020
Q1 		$39.2M Sell
1,709,765
-78,878
-4% -$1.95M 1.82% 16
2019
Q4 		$50.7M Buy
1,788,643
+249
+0% +$6.26K 2.02% 17
2019
Q3 		$38.4M Sell
1,788,394
-81,286
-4% -$2.27M 2.34% 11
2019
Q2 		$54.5M Buy
+1,869,680
New +$50.2M 3.13% 8

Other funds holding STOK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

Cormorant Asset Management's STOK Position: Q3 2025 in Review

Cormorant Asset Management sold out of Stoke Therapeutics (STOK) in Q3 2025, closing a stake of 254,161 shares — an estimated $2.88M sold.

Cormorant Asset Management first reported a position in STOK in Q2 2019 and held it in 25 quarters. The position peaked at $89M in Q4 2020. 151 funds tracked by Wall St. Rank hold STOK as of Q3 2025.

  • Cormorant Asset Management reported no remaining Stoke Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Cormorant Asset Management sold 254,161 Stoke Therapeutics shares in Q3 2025, an estimated $2.88M.
  • Cormorant Asset Management first reported a position in Stoke Therapeutics in Q2 2019 and held it in 25 quarters.
  • Cormorant Asset Management's Stoke Therapeutics position peaked at $89M in Q4 2020.
  • 151 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2025.

Based on Cormorant Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.